![]() |
市场调查报告书
商品编码
1324364
到 2030 年模块化实验室自动化市场预测:按设备和软件、用途和地区进行的全球分析Modular Laboratory Automation Market Forecasts to 2030 - Global Analysis By Equipment and Software, Application and By Geography |
根据 Stratistics MRC 的数据,2023 年全球模块化实验室自动化市场规模为 38.9 亿美元,预计在预测期内将以 8.1% 的年复合成长率增长,到 2030 年达到 67.1 亿美元。
模块化实验室自动化是一种常用于药物研发、诊断、基因组学等领域的实验室自动化流程。任何能够提高实验室生产力和效率同时几乎不需要人工干预的设备、软件或设备都被称为“实验室自动化”。机器人、输送机、软件和其他设备都是自动化的一部分。
实验室始终需要更快、更有效的程序,尤其是在製药、生物技术和临床研究行业。模块化实验室自动化提供的自动化单调且耗时的任务的能力将在预测期内显着提高该市场的吞吐量和整体效率。
实施模块化实验室自动化系统时,设备、软件和集成的初始投资可能很高。对于小型实验室或预算有限的实验室来说,初始成本可能是一个主要障碍。这些要素限制了市场的扩张。
由于机器人、传感器技术和整合能力方面的技术进步,模块化实验室自动化系统现在更具适应性、可靠性和经济性。由于这些发展,各种实验室过程中自动化的应用范围正在扩大。此外,自动化系统可以帮助提高资料可追溯性和准确性,提高合规性和审核准备度。
实验室行业的自动化协议和接口通常没有标准化。因此,各种自动化组件之间可能会出现兼容性问题,阻碍自动化系统的顺利整合。此外,兼容性问题和定制解决方案的需求可能会增加实施时间和成本。
COVID-19 大流行加速了医学研究和开发,同时给製药公司和临床实验室带来了额外的压力。由于人们对酶标仪、自动液体处理和机器人技术的兴趣日益浓厚,确保实现 TAT 降低非常重要。与此同时,流行病减少了自动化和技术方面的支出,降低了医院和卫生系统的收入和利润率。这将影响模块化实验室自动化的未来市场。
在预测期内,自动液体处理机市场预计将是最大的。液体处理机经常用于化学和生物化学实验室。在实验室中,自动液体处理机器人协助分配样品和其他液体。自动液体处理机可缩短週期时间并提高精度。此外,液体处理器可以容纳低至纳升的各种体积,展示了其在分配操作中的价值。
预计临床诊断领域在预测期内将出现良好的增长。模块化实验室自动化广泛应用于临床诊断,因为它可以优化实验室工作流程、提高生产力、提高准确性并减少人为错误的机会。此外,模块化自动化可用于自动化各种检测和临床化学测试,使实验室能够快速处理大量测试,而无需用户参与。
由于所有最终用户领域广泛采用最尖端科技,预计北美将主导模块化实验室自动化市场。预计该市场将受到对尖端基因组学、蛋白质组学和表观遗传学研究的投资、对环境问题日益关注以及全球最大的製药和生物技术公司和学术机构的集中推动。
亚太地区对实验室自动化解决方案的需求预计将增加,这主要是由于製药行业的爆炸性增长。持续的人口和经济趋势、新的医疗改革以及政府五年计划中概述的政策预计将支持市场扩张。由于市场的快速扩张,实验室自动化解决方案供应商有了扩大足蹟的新机会。
According to Stratistics MRC, the Global Modular Laboratory Automation Market is accounted for $3.89 billion in 2023 and is expected to reach $6.71 billion by 2030 growing at a CAGR of 8.1% during the forecast period. Modular Lab Automation is a type of laboratory automation process frequently used in drug discovery, diagnostics, genomics, etc. Any device, piece of software, or piece of equipment that requires little to no human interaction while increasing lab productivity and efficiency is referred to as "laboratory automation." Robots, conveyors, software, and other devices are all part of automation.
Faster and more effective procedures are constantly needed in laboratories, particularly those in the pharmaceutical, biotechnology, and clinical research industries. The ability to automate monotonous and time-consuming tasks is provided by modular laboratory automation, significantly boosting throughput and overall effectiveness of this market during the forecast period.
Equipment, software, and integration are frequently expensive up front when implementing modular laboratory automation systems. For smaller labs or those with tighter budgets, the initial cost can be a major barrier. Such factors limit market expansion.
Modular laboratory automation systems are now more adaptable, dependable, and economical thanks to technological advancements in robotics, sensor technologies, and integration capabilities. The range of applications for automation in different laboratory processes has increased as a result of these developments. Moreover, automation systems can also help increase data traceability and accuracy, boosting compliance and audit readiness.
Automation protocols and interfaces are frequently not standardised in the laboratory industry. As a result, there may be compatibility problems between various automation components, which could obstruct the smooth integration of automation systems. Moreover, compatibility problems and the need for customised solutions can also increase the time and cost of implementation.
The COVID-19 pandemic has sped up medical research and development while putting more pressure on pharmaceutical firms and clinical labs. Making sure a shorter TAT is achieved has gained importance as a result of the increased interest in microplate readers, automated liquid handling, and robots. On the other hand, the epidemic has led to lower spending on automation and technology, as well as lower revenues and margins for hospitals and health systems. This has an effect on the future market for modular laboratory automation.
The automated liquid handlers segment is expected to be the largest during the anticipated period. Laboratories that work with chemicals and biochemistry frequently employ liquid handlers. In laboratories, automated liquid handling robots assist with dispensing samples and other liquids. Automated liquid handlers reduce cycle times and increase precision. Additionally, liquid handlers can work with a variety of volumes, down to nanolitres, demonstrating their value in dispensing operations.
The clinical diagnostics segment is expected to witness lucrative growth during the forecast period. The ability of modular laboratory automation to optimise laboratory workflows, increase productivity, increase accuracy, and decrease the possibility of human error has led to its widespread use in clinical diagnostics. Additionally, modular automation can be used to automate different immunoassays and clinical chemistry tests, enabling laboratories to process a large number of tests quickly and with little user involvement.
Due to widespread adoption of cutting-edge technologies across all end-user segments, North America is anticipated to dominate the modular laboratory automation market. The market is predicted to be driven by investments in cutting-edge genomics, proteomics, and epigenetics research, a rise in the focus on environmental concerns, and the concentration of some of the biggest pharmaceutical and biotechnology companies in the world as well as academic institutions in the region.
The demand for lab automation solutions is expected to rise in the Asia-Pacific region, primarily as a result of the region's explosive growth in the pharmaceutical industry. The continuation of demographic and economic trends, new healthcare reforms, and the policies outlined in the government's five-year plan are all anticipated to fuel market expansion. Vendors of lab automation solutions now have new opportunities to increase their footprint thanks to the rapidly expanding market.
Some of the key players profiled in the Modular Laboratory Automation Market include: Agilent Technologies, Inc., Beckman Coulter, Inc., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Eppendorf AG, F. Hoffmann-La Roche Ltd., Honeywell International Inc., Hudson Robotics, Inc., PerkinElmer, Inc., QIAGEN N.V., Shimadzu Scientific Instruments, Siemens Healthineers, Synchron Lab Automation, Tecan Group Ltd. And Thermo Fisher Scientific, Inc.
In June 2022, MegaRobo Technologies Ltd announced the completion of a USD 300 million Series C fundraising round. MegaRobo would use the funds to continue its R&D investments, capacity growth, and global expansion. MegaRobo has offered the life sciences industry a comprehensive set of automation solutions. Ranging from benchtop workflow automation for simple workflows to a fully automated platform for complex workflows in large system journey applications, with plans to expand into the next-generation life sciences infrastructure system for R&D and AI drug development.
In May 2022, Global life science innovators MGI Tech Co. Ltd (MGI) and King Abdullah International Medical Research Center (KAIMRC) signed a Memorandum of Understanding (MOU) to form a strategic collaboration in the domains of genomic science and biotechnology. The MOU anticipates establishing a high-throughput sequencing center in KAIMRC, which may accommodate MGI's technology platforms, including DNBSEQ sequencing, laboratory automation, and bioinformatics products. Driven by MGI's proprietary DNBSEQ technology, the partnership will employ MGI's platform to improve genome sequencing and data quality across a wide range of applications.